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Cytarabine (cytosine arabinoside) is one of the most effective drugs for the treatment of acute myeloid leukemia.
The standard dose of cytarabine used to treat this leukemia is 100 mg per square meter. In an attempt to improve
the effectiveness of cytarabine against acute myeloid leukemia, a high-dose treatment (3,000 mg per square meter)
was introduced into therapy. The side effects of high-dose cytarabine was a major concern, especially its
neurological toxicity. A review of recent clinical trials indicates that this high-dose cytarabine can be replaced by
the intermediate-dose of 1,000 mg per square meter without loss of efficacy and with less toxicity. This is an
important step to improve the efficacy of cytarabine for the treatment of acute myeloid leukemia. Despite the
improvements in the therapy for this leukemia, the current overall survival rate for adult patients is less than 30%.
To optimize the cytarabine therapy, it is important to determine how some leukemic stem cells survive treatment.
Preclinical data suggest that survival of the leukemic stem cells could be due to the long 12 hour interval between
infusions of cytarabine, which permits some leukemic cells to escape its S phase specific action. Among the other
factors that can lead to leukemic cell survival are the high levels in the liver and spleen of cytidine deaminase, the
enzyme that inactivates cytarabine and drug resistance due to deficiency in deoxycytidine kinase, the enzyme that
activates the prodrug, cytarabine. Several approaches are proposed in this commentary to overcome these
impediments with the goal of increasing the effectiveness of cytarabine for the treatment of acute myeloid leukemia.
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Cytarabine (cytosine arabinoside, ARA-C) has been used
for the treatment of acute myeloid leukemia (AML) for
approximately 40 years [1]. One of the first standard dose-
schedules (SD) of ARA-C was 100 mg per square meter
per day administered as a continuous i.v. infusion for
7 days [1].
The rationale for the use of HD-ARA-C for the treat-
ment of AML was first proposed in 1974 [2]. High-dose
(HD) ARA-C was introduced into clinical therapy for
AML in 1979 and the early 1980s [3].
Several investigators performed pilot studies in patients
with AML using intensive doses of ARA-C and reported
several positive results [4-6]. The most comprehensive clin-
ical study was published in 1983 by Herzig and colleagues.Correspondence: richard.l.momparler@umontreal.ca
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reproduction in any medium, provided the orThey determined that the maximal tolerated dose (MTD)
of ARA-C was 3,000 mg per square meter administered as
a one-hour infusion every 12 hours for 6 days [6]. The
MTD of a drug is not necessarily its most effective thera-
peutic dose. One of the major concerns of this HD-ARA-C
was its toxicity. In addition to myelosuppression, severe
neurologic toxicity was also observed in some patients
treated with HD-ARA-C [7]. This CNS toxicity was dose-
related because it was more severe at the higher ARA-C
dose of 4,500 mg per square meter [6]. The pathogenesis
of this CNS toxicity remains to be clarified and may be
due to the formation of minor metabolites of ARA-C, such
as ARA-C-diphosphocholine. Normal cells treated with
ARA-C can synthesize significant amounts of ARA-C-
diphosphocholine [8], which can interfere with the function
of the normal metabolite cytidine diphosphocholine. In
support of this hypothesis is the interesting data on the
use cytidine diphosphocholine (citicoline) for its “brain-
repair” action in the treatment of stroke [9,10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ARA-C observed in some patients with AML, clinical in-
vestigators initiated studies using an intermediate dose
(ID) of ARA-C in the range of 1,000 to 2,000 mg per
square meter [11]. In a recent commentary by Löwenberg
entitled: “Sense and nonsense of high-dose cytarabine for
acute myeloid leukemia,” he states that the data from sev-
eral clinical trials indicate that it does not make sense to
use HD-ARA-C and that it can be replaced by ID-ARA-C
with similar clinical efficacy but less toxicity [12]. Investi-
gations of the metabolism of ARA-C to its active inhibitor,
ARA-CTP, by kinases in myeloid leukemic cells from
treated patients support this conclusion [13]. This latter
study showed that at the 1,000 mg per square meter dose
of ARA-C, maximal formation of ARA-CTP is achieved
and not increased by the use of the 3,000 mg per square
meter dose. During the infusion of HD-ARA-C the steady
state plasma level of ARA-C is >100 μM [14]. The en-
zymes involved in the activation of ARA-C are completely
saturated at the lower dose. This is an interesting example
of how in vitro studies on leukemic cells from patients can
provide useful guidelines to optimize the dose of ARA-C
for the treatment of AML.
The replacement of HD-ARA-C with ID-ARA-C to
improve its therapeutic index is an important advance-
ment for the treatment of AML. The next key question
to consider is whether there are other ways to further
improve the effectiveness of ARA-C therapy for AML.
To make further progress it is important to determine
why patients with AML relapse after treatment with
ARA-C. In Table 1 is a list of different mechanisms by
which leukemic stem cells can possibley “escape” ARA-C
treatment and suggestions to overcome these potential im-
pediments to improve the effectiveness of chemotherapy.Duration of interval between ARA-C infusions
The long 12-hour interval between the one-hour infusions
of HD-ARA-C provides a window for leukemic stem cells
to escape its therapeutic action. Because ARA-C has a
short plasma half-life [7], 3 hours after the end of the infu-
sion its concentration falls below the therapeutic range.
Cell kinetic analysis shows that the S phase of AML cells
from some patients can be as short as 8 h [15]. Because
ARA-C is an S phase specific agent, some leukemic cells
can progress through this phase during the 12-hour in-
terval with minimal or no exposure to cytotoxic concen-
trations. The original model for intense dose ARA-C for
the treatment of AML used a 6-hour interval between
drug infusions to reduce the probability of leukemic cells
passing through the S phase without exposure to cytotoxic
concentrations of this analogue [2]. Laboratory studies
using a colony assay show that reduction of the inter-
val between ARA-C exposures to less than 12 hoursincreases its cytotoxic action against human myeloid
leukemic cells [16].
Drug resistance to ARA-C
Drug resistance to ARA-C can occur by several different
mechanisms [17]. ARA-C is a prodrug that is activated
by phosphorylation by deoxycytidine (CdR) kinase. Be-
cause the human CdR kinase gene is located on chromo-
some 4, there are two copies of the gene in the cell [18].
Complete drug resistance due to a deficiency in CdR
kinase is rare because it requires the gene inactivation of
both alleles. It is important to determine if relapse after
ARA-C therapy is due to a deficiency in CdR kinase. A
simple in vitro drug sensitivity test can be performed on
blood leukemic blasts. The leukemic cells are incubated
with radioactive thymidine and the inhibition of its in-
corporation into the DNA by ARA-C is determined [19].
Leukemic cells that show some deficiency in CdR kinase
show less inhibition of DNA synthesis by ARA-C. We
used this in vitro test to detect CdR kinase deficiency in
leukemic cells from patients treated with the related CdR
analogue, 5-aza-2’-deoxycytidine (decitabine) [19,20]. Re-
sistance to ARA-C due to deficiency of CdR kinase in AML
cells has also been reported by other investigators [18].
One interesting approach to overcome the problem of
ARA-C drug resistance due to a deficiency in CdR kinase
is to use 3-deazauridine (3-DU) [21]. 3-DU is a competi-
tive inhibitor of CTP synthetase that reduces the intracel-
lular levels of CTP and dCTP. Wild type leukemic cells
can escape the cytotoxic action of 3-DU by using CdR kin-
ase to phosphorylate the CdR present in the extracellular
fluid. However, leukemic cells deficient in CdR kinase die
due to “dCTP starvation” when treated with 3-DU [21].
The drug-resistant leukemic cells are more sensitive to the
chemotherapeutic action of 3-DU than the wild type
leukemic cells [20,21]. 3-DU also enhances the cytotoxic
action of ARA-C on AML cells by increasing it incorpo-
ration into DNA [22].
Another mechanism of drug resistance to ARA-C is due
to an increase in the intracellular level of dCTP in leukemic
cells [23]. dCTP has a dual action to antagonize the action
of ARA-C. First, it acts as a natural competitive inhibitor of
the incorporation of ARA-CTP into DNA. Second, dCTP
is a feedback inhibitor of CdR kinase that reduces the phos-
phorylation of ARA-C. As discussed above, 3-DU can re-
verse both these effects.
The deamination of ARA-C to uracil arabinoside by
cytidine (CR) deaminase results in a complete loss of an-
tineoplastic activity. Cells that overexpress CR deami-
nase show signs of drug resistance to ARA-C [24,25].
We detected an increased expression of CR deaminase in
leukemic blasts after treatment with decitabine [19].
Tetrahydrouridine, a potent inhibitor of CR deaminase, can
be used to overcome this type of drug resistance [26,27].
Table 1 Possible mechanisms by which leukemic stem
cells survive after ARA-C treatment and approaches to
optimize therapy
Treatment to reduce
Survival mechanisms leukemic cell survival References
12-h interval between ARA-C
infusions too long
reduce interval [16]
deficiency in CdR kinase 3-DU + ARA-C [20-22]
increase in dCTP 3-DU + ARA-C [20-22]
increase CR deaminase THU + ARA-C [24,25]
CR deaminase inactivation
of ARA-C in liver
THU + ARA-C [24,25]
block in cell cycle progression
G1 to S phase
intermittent ARA-C, DAC [30]





resistance to apoptosis DAC prime ARA-C, DAC [36,40]
Abbreviations: h hour, 3-DU 3-deazauridine, THU tetrahydrouridine, DAC decitabine.
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and spleen
The liver and spleen contain very high levels of CR deami-
nase [28] that provide a biochemical sanctuary in these or-
gans for leukemic cells due to the deamination of ARA-C
to very low concentrations with minimal or no antileuke-
mic activity [27]. This event probably occurs frequently
when SD-ARA-C is used because the plasma level of
ARA-C is low. Tetrahydrouridine can be used to enhance
the antineoplastic action of CdR analogues on tumor cells
present in the liver and spleen [27].
ARA-C can block progression of some leukemic cells from
G1 to S phase
The regulation of the progression of cells from G1 to S
phase is a complex event that involves a series of activa-
tions of different cyclins by phosphorylation [29]. The
inhibition of DNA replication by ARA-C in leukemic cells
at this G1/S phase check point can lead to a block in the
progression of some leukemic cells into S phase. Evidence
for this rare event comes from studies that compare the an-
tineoplastic activity of ARA-C and decitabine in leukemic
cells [30]. Both these agents are deoxycytidine analogues
and S phase specific agents because their antileukemic ac-
tion is due to their incorporation into DNA. However, their
mechanisms of action are different; ARA-C inhibits DNA
synthesis whereas decitabine inhibits DNA methylation.
Because both of these agents target the same cohort of
leukemic cells in the S phase, they should produce an iden-
tical loss of survival at equal exposure times and thera-
peutic concentrations. However, colony assays show that
more myeloid leukemic cells survive after ARA-C treat-
ment than after decitabine [30]. Additionally, in a mouse
model of L1210 leukemia using the same duration of infu-
sion, decitabine cured the mice, but ARA-C at its MTD did
not [31]. The partial G1/S phase block by ARA-C can per-
mit a small fraction of the leukemic cells to escape its che-
motherapeutic action. There are two possible approaches
than could be used to overcome this problem. First, it is
possible that some leukemic cells may recover from this
block when an intermittent ARA-C treatment is used ra-
ther than a continuous exposure. Second, it is possible to
replace ARA-C with decitabine, whose epigenetic action
does not block progression of the G1 cell into S phase [32].
It would be interesting to use a colony assay to compare
the antineoplastic activity of ARA-C and decitabine on
leukemic cells to identify the patients that would benefit
from decitabine therapy.
High frequency of leukemic stem cells
Research shows that upon analysis of leukemic cells from
patients with AML, only a small fraction of the cells func-
tion as leukemic stem cells [33]. Long-term survival of
patients with leukemia is dependent on the completeeradication of the leukemic stem cells by chemotherapy. It
has been reported that a high stem cell frequency in AML
and acute lymphoblastic leukemia predicts a poor survival
rate [34,35]. We do not fully understand why AML pa-
tients with adverse cytogenetics are less responsive to
ARA-C therapy than AML patients with a normal karyo-
type [1]. One possible explanation is that these high-risk
AML patients have a higher frequency of leukemic stem.
To completely eradicate the leukemic stem cells with
ARA-C in the high-risk AML patients, one has to increase
the clinical efficacy of the chemotherapy. One approach to
accomplish this objective is to use ARA-C in combination
with 3-DU, which enhances the cytotoxic action of ARA-
C on AML cells [22]. Another interesting approach is to
use epigenetic priming with decitabine prior to SD-ARA-
C treatment of patients with AML [36]. This latter ap-
proach was used in a phase I study and produced 83% CR
in patients with less-than-favorable risk of AML.
Resistance to apoptosis
The suppression of apoptosis in malignant cells can occur
by epigenetic silencing. Aberrant DNA methylation was
reported to silence the pro-apoptotic gene, FOXO3 [37]
and to down-regulate the TRAIL pathway [38]. Treatment
with decitabine can lead to the reactivation of these pro-
apoptotic pathways [37,38]. An interesting approach to
overcome the problem of ARA-C resistance to apoptosis
is to use epigenetic priming with decitabine to reactivate
the apoptotic pathway prior to the ARA-C therapy [36].
Mutations in p53 are associated with resistance to ARA-C
therapy in patients with AML [39]. This drug resistance is
due, in part, to interference with the normal apoptotic
pathway in AML cells. Decitabine was shown to be effect-
ive against p53-null AML cells and more active than
ARA-C [40]. This epigenetic agent can be used to treat
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apoptosis by ARA-C.
Conclusion
To improve the effectiveness of chemotherapy for the
treatment of AML, we have to learn why ARA-C does
not completely eradicate all the leukemic stem cells. In
vitro tests on leukemic cells from AML patients before
and after relapse can give insight on how some leukemic
cells survive ARA-C therapy. Several approaches can be
investigated to improve the efficacy of ARA-C (Table 1).
In addition to these approaches, the long interval (4 weeks)
between cycles of ARA-C therapy can permit surviving
leukemic cells to expand unimpeded, which can also be
a source for treatment failure. Recent results indicate that
it is possible to use very low (metronomic) doses (1-3X/
week) of decitabine with good responses in patients with
myelodysplastic syndrome [41]. This low dose decitabine
can maintain or increase self-renewal of normal hemato-
poietic stem cells [42]. An interesting alternative is to use
non-toxic genistein to slow the progression of leukemia
between cycles of ARA-C [43]. It would be of interest to
perform pilot studies using novel ARA-C regimens on co-
horts of high-risk AML patients that have a limited life ex-
pectancy. These pilot studies to optimize ARA-C therapy
can possibly lead to a better understanding of the pharma-
cology of this analogue and leukemogenesis and lead to an
improved survival in patients with AML.
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ADDENDUM
An excellent example of an in vitro colony assay on leukemic cells from
patients to evaluate the efficacy of chemotherapy is shown in the
publication by: Craddock C, Quek L, Goardon N, et al: Azacitidine fails to
eradicate leukemic stem/progenitor cell populations in patients with
acute myeloid leukemia and myelodysplasia. Leukemia. 2013, 27:1028-1036.
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